Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | CBFB | Q13951 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15302917 | 0.85 | PIK3CD (0.49) | KDM4ENPC1PIK3CDPIK3CGPIK3CA | |
| SCHEMBL20067852 | 0.85 | PIK3CD (0.49) | KDM4ENPC1PIK3CDPIK3CGPIK3CA | |
| SCHEMBL2729736 | 0.81 | PIK3CD (0.51) | PIK3CDPIK3CGPIK3CAPIK3CBMETAP2 | |
| SCHEMBL15303018 | 0.80 | RXFP1 (0.36) | KDM4EMEN1KMT2AGAAMAPT | |
| SCHEMBL15303365 | 0.79 | KDM4E (0.49) | KDM4ENPC1PIK3CDPIK3CGPIK3CA | |
| SCHEMBL15303159 | 0.79 | KDM4E (0.49) | KDM4ENPC1PIK3CDPIK3CGPIK3CA | |
| SCHEMBL15302889 | 0.79 | KDM4E (0.49) | KDM4ENPC1PIK3CDPIK3CGPIK3CA | |
| SCHEMBL16586654 | 0.77 | PIK3CD (0.41) | PIK3CDPIK3CGPIK3CAPIK3CBALDH1A1 | |
| SCHEMBL23212709 | 0.75 | LMNA (0.42) | KDM4ENPC1METAP1MEN1KMT2A | |
| SCHEMBL16597049 | 0.72 | KDM4E (0.59) | KDM4ENPC1PIK3CDPIK3CGPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2834231-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2834231-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2834231-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2015-02-11 | — | — | EP | disclosed |
| US-8835432-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835432-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835432-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20140206694-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206694-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206694-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8754089-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8716290-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716290-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-05-06 | — | — | US | disclosed |
| WO-2013152150-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013152150-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-10-10 | — | — | WO | disclosed |
| US-20130267524-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130267524-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130267524-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-10-10 | — | — | US | disclosed |
| EP-2445898-A2 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES AS PI3K INHIBITORS | Amgen, Inc (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20120083502-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-05 | — | — | US | disclosed |
| WO-2010151735-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267524-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | KDM4E 1806/4885NPC1 4505/4885PIK3CD 16/4885 |
| US-20140206694-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | KDM4E 1806/4885NPC1 4505/4885PIK3CD 16/4885 |
| US-20120083502-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | KDM4E 1436/4885NPC1 4528/4885PIK3CD 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.